- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00985530
Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia
October 28, 2013 updated by: Jessica Altman, Northwestern University
A Phase I Trial of Tamibarotene and Arsenic Trioxide for the Treatment of Relapsed Acute Promyelocytic Leukemia
Subjects have acute promyelocytic leukemia (APL) that has come back (relapsed) after initial treatment or has not gone away with initial therapy.
This research study involves testing an investigational drug called Tamibarotene in combination with standard treatment for relapsed APL called arsenic trioxide.
Tamibarotene has been approved in Japan to treat patients with relapsed APL since April 2005.
Tamibarotene is in the same family of drugs as all-trans retinoic acid (ATRA), a medication that subjects received previously in their treatment.
ATRA and tamibarotene both cause the APL cells to differentiate (or become) normal non-leukemia cells.
Laboratory studies of tamibarotene have shown to be effective in APL.
The purpose of this study is to determine if tamibarotene in combination with arsenic trioxide is safe and effective.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
4
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Must have diagnosis of relapsed APL
- Must have completed any prior cancer treatment at least 6 months prior to study
- Must have had prior treatment that included ATRA
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1
Tamibarotene + Arsenic Trioxide
|
Self-administered tablets BID (approximately one hour after breakfast & dinner) during each 6 week cycle
Administered intravenously Monday thru Friday at 0.15 mg/kg - 30 doses per cycle.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the safety and feasibility of combining tamibarotene and arsenic (ATO) for the treatment of patients with relapsed APL.
Time Frame: Once the MTD has been reached.
|
Once the MTD has been reached.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2009
Primary Completion (Actual)
May 1, 2011
Study Completion (Actual)
May 1, 2011
Study Registration Dates
First Submitted
September 25, 2009
First Submitted That Met QC Criteria
September 25, 2009
First Posted (Estimate)
September 28, 2009
Study Record Updates
Last Update Posted (Estimate)
October 30, 2013
Last Update Submitted That Met QC Criteria
October 28, 2013
Last Verified
October 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NU 08H9
- NCI-2010-01852 (Other Identifier: NCI CTRP#)
- STU00012159 (Other Identifier: Northwestern University IRB#)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Promyelocytic Leukemia
-
German AML Cooperative GroupUnknownRelapsed Acute Promyelocytic Leukemia | Refractory Acute Promyelocytic LeukemiaGermany
-
South China Children's Leukemia GroupCompletedChildhood Acute Promyelocytic LeukemiaChina
-
Christian Medical College, Vellore, IndiaUnknownRelapsed Acute Promyelocytic LeukemiaIndia
-
Instituto Nacional de Cancerologia de MexicoCompletedPromyelocytic Leukemia, AcuteMexico
-
PETHEMA FoundationCompletedAcute Promyelocytic LeukemiaSpain
-
Peking University People's HospitalMinistry of Science and Technology of the People´s Republic of ChinaNot yet recruitingAcute Promyelocytic Leukaemia
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingAcute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARAUnited States, Canada, Saudi Arabia, Puerto Rico, Australia, New Zealand
-
Grupo Argentino de Tratamiento de la Leucemia AgudaRecruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Acute Promyelocytic Leukemia With PML-RARAUnited States
-
The University of Hong KongRecruitingAcute Promyelocytic LeukemiaHong Kong
Clinical Trials on Tamibarotene
-
St. Marianna University School of MedicineUnknownHTLV-I-Associated MyelopathyJapan
-
R&R Inc.Completed
-
Kinki UniversityUnknown
-
Osaka City UniversityUnknown
-
Rege Nephro Co., Ltd.RecruitingAutosomal Dominant Polycystic Kidney Disease (ADPKD)Japan
-
CytRxCompletedAcute Promyelocytic LeukemiaUnited States
-
CytRxTerminatedStage IV Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer With Pleural EffusionUnited States, Mexico, India, Ukraine, Bulgaria, Russian Federation
-
Pulmotect, Inc.United States Department of DefenseCompleted
-
Syros PharmaceuticalsRecruitingMyelodysplastic SyndromesUnited States, Spain, Belgium, Israel, France, United Kingdom, Austria, Czechia, Italy, Poland, Canada, Hungary, Germany
-
Syros PharmaceuticalsRecruitingAcute Myeloid LeukemiaUnited States, France